Alliance Global Partners upgraded Obalon Therapeutics from Neutral to Buy
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
Alliance Global Partners upgraded Obalon Therapeutics from Neutral to Buy
4 - ReShape Lifesciences Inc. (0001427570) (Issuer)
3 - ReShape Lifesciences Inc. (0001427570) (Issuer)
3 - ReShape Lifesciences Inc. (0001427570) (Issuer)
SAN CLEMENTE, CA and SAN DIEGO, CA / ACCESSWIRE / June 15, 2021 / ReShape Lifesciences Inc. (OTCQB:RSLS) and Obalon Therapeutics, Inc. (NASDAQ:OBLN) announced today the anticipated closing of their previously announced merger to be effective after the close of the market today, June 15, 2021. The shares of common stock of the combined company are expected to commence trading on The Nasdaq Capital Market on Wednesday, June 16, 2021, under the name ReShape Lifesciences Inc. and the trading symbol "RSLS."Immediately following the effective time of the merger, existing ReShape stockholders will own 51% and existing Obalon stockholders will own 49% of the outstanding shares of common stock of the
SAN CLEMENTE, CA and SAN DIEGO, CA / ACCESSWIRE / June 8, 2021 / ReShape Lifesciences Inc. (OTCQB:RSLS) and Obalon Therapeutics, Inc. (NASDAQ:OBLN) announced today that the parties anticipate the closing of their previously announced merger to occur promptly after approval of their pending Nasdaq listing application. While there can be no assurance that the listing application will be approved, Nasdaq approval is the sole remaining condition to closing in the merger agreement (other than conditions that the parties anticipate being satisfied at the closing). Upon the closing of the merger, shares of common stock of the combined company are expected to commence trading on The Nasdaq Capital M
SAN DIEGO, CA / ACCESSWIRE / May 24, 2021 / Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable gas-filled intragastric balloon system for the treatment of obesity, is taking this opportunity to remind its stockholders to vote on all the proposals related to the proposed merger with ReShape Lifesciences Inc. in advance of the upcoming reconvened special meeting of Obalon stockholders (the "Special Meeting") on May 25, 2021, at 8:30 a.m. PT.All stockholders are highly encouraged to vote by phone or email on this critical transaction. Without the required stockholder approval, the merger will not be able t
8-K - ReShape Lifesciences Inc. (0001427570) (Filer)
8-K - OBALON THERAPEUTICS INC (0001427570) (Filer)
8-K - OBALON THERAPEUTICS INC (0001427570) (Filer)
SC 13G/A - ReShape Lifesciences Inc. (0001427570) (Subject)
SC 13D/A - ReShape Lifesciences Inc. (0001427570) (Subject)
SC 13D - ReShape Lifesciences Inc. (0001427570) (Subject)
SAN DIEGO, March 12, 2021 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its financial results for the fourth quarter and full year ended December 31, 2020. On November 10, 2020, the Company signed a non-binding term sheet for merger with ReShape Lifesciences Inc. and, on January 20, 2021, announced that a definitive agreement had been signed on January 19, 2020 for a merger with ReShape Lifesciences Inc. Financial results for the fourth quarter of 2020Revenue for the fourth quarter of 2020 w